MNCs Consider Different Prices For Different Indian Drug Buyers
This article was originally published in PharmAsia News
Executive Summary
Multinational drug makers are considering a split of their drug pricing decisions in India, charging differently for the government, hospitals and patient-access programs. The differentiation is planned primarily for AIDS and cancer drugs as a way to gain back a greater share of the Indian market from generics makers. MNCs generally have been charging about as much for their drugs in India as in the rest of the world, but many have realized India has proved to be a smaller market than anticipated. A consultant said the firms realize they have to arrange their prices strategically if they are to compete. (Click here for more